Literature DB >> 22653667

Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.

Meghna Talekar1, Srinivas Ganta, Amit Singh, Mansoor Amiji, Jackie Kendall, William A Denny, Sanjay Garg.   

Abstract

PURPOSE: Ovarian cancer is a debilitating disease, which needs multi-pronged approach of targeted drug delivery and enhanced efficacy with the use of combination therapeutics. In this study, we have examined the anticancer activity of PIK75 incorporated in surface functionalized nanoemulsions for targeted delivery to SKOV-3 cells. A pro-apoptotic molecule C(6)-ceramide was also co-delivered to augment therapeutic efficacy.
METHODS: EGFR and FR functionalized nanoemulsions incorporating PIK75 and C(6)-ceramide were characterized for particle size, surface charge, entrapment efficiency and morphology. Fluorescence and quantitative uptake studies were conducted in SKOV-3 cells to determine intracellular distribution. Cell viability was assessed using MTT assay while mechanism of cytotoxicity was evaluated using capsase-3/7, TUNEL and hROS assay.
RESULTS: Cytotoxicity assay showed 57% decrease in IC(50) value of PIK75 following treatment with EGFR targeted nanoemulsion and 40% decrease following treatment with FR targeted nanoemulsion. Combination therapy with PIK75 and ceramide enhanced the cytotoxicity of PIK75 compared to therapy with individual formulations. The increase in cytotoxicity was attributed to increase in cellular apoptosis and hROS activity.
CONCLUSION: The results of this study showed that the targeted system improved cytotoxicity of PIK75 compared to the non-targeted system. Combination therapy with ceramide augmented PIK75's therapeutic activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653667     DOI: 10.1007/s11095-012-0793-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

Review 1.  Disposition characteristics of emulsions and incorporated drugs after systemic or local injection.

Authors:  S Kawakami; F Yamashita; M Hashida
Journal:  Adv Drug Deliv Rev       Date:  2000-12-06       Impact factor: 15.470

Review 2.  Taming the PI3K team to hold inflammation and cancer at bay.

Authors:  Emilio Hirsch; Elisa Ciraolo; Alessandra Ghigo; Carlotta Costa
Journal:  Pharmacol Ther       Date:  2008-03-05       Impact factor: 12.310

3.  Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.

Authors:  Jackie D Kendall; Gordon W Rewcastle; Raphael Frederick; Claire Mawson; William A Denny; Elaine S Marshall; Bruce C Baguley; Claire Chaussade; Shaun P Jackson; Peter R Shepherd
Journal:  Bioorg Med Chem       Date:  2007-09-04       Impact factor: 3.641

Review 4.  Ceramide involvement in apoptosis and apoptotic diseases.

Authors:  Karin Thevissen; Isabelle E J A François; Joris Winderickx; Christophe Pannecouque; Bruno P A Cammue
Journal:  Mini Rev Med Chem       Date:  2006-06       Impact factor: 3.862

5.  Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.

Authors:  Srinivas Ganta; Harikrishna Devalapally; Mansoor Amiji
Journal:  J Pharm Sci       Date:  2010-11       Impact factor: 3.534

6.  Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.

Authors:  Michael E Werner; Shrirang Karve; Rohit Sukumar; Natalie D Cummings; Jonathan A Copp; Ronald C Chen; Tian Zhang; Andrew Z Wang
Journal:  Biomaterials       Date:  2011-08-16       Impact factor: 12.479

Review 7.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

8.  A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner.

Authors:  Nilesh M Dagia; Gautam Agarwal; Divya V Kamath; Anshu Chetrapal-Kunwar; Ravindra D Gupte; Mahesh G Jadhav; Shruta S Dadarkar; Jacqueline Trivedi; Asha A Kulkarni-Almeida; Firuza Kharas; Lyle C Fonseca; Sanjay Kumar; Mandar R Bhonde
Journal:  Am J Physiol Cell Physiol       Date:  2010-01-20       Impact factor: 4.249

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

10.  Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.

Authors:  Lilian E van Vlerken; Zhenfeng Duan; Steven R Little; Michael V Seiden; Mansoor M Amiji
Journal:  Mol Pharm       Date:  2008-07-11       Impact factor: 4.939

View more
  6 in total

1.  A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.

Authors:  Alejandra M Petrilli; Marisa A Fuse; Mathew S Donnan; Marga Bott; Nicklaus A Sparrow; Daniel Tondera; Julia Huffziger; Corina Frenzel; C Siobhan Malany; Christophe J Echeverri; Layton Smith; Cristina Fernández-Valle
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy.

Authors:  Srinivas Ganta; Meghna Talekar; Amit Singh; Timothy P Coleman; Mansoor M Amiji
Journal:  AAPS PharmSciTech       Date:  2014-02-08       Impact factor: 3.246

Review 3.  Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases.

Authors:  Meghna Talekar; Thanh-Huyen Tran; Mansoor Amiji
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

4.  EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.

Authors:  Srinivas Ganta; Amit Singh; Praveen Kulkarni; Amanda W Keeler; Aleksandr Piroyan; Rupa R Sawant; Niravkumar R Patel; Barbara Davis; Craig Ferris; Sara O'Neal; William Zamboni; Mansoor M Amiji; Timothy P Coleman
Journal:  Pharm Res       Date:  2015-03-04       Impact factor: 4.200

5.  Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer.

Authors:  Srinivas Ganta; Amit Singh; Niravkumar R Patel; Joseph Cacaccio; Yashesh H Rawal; Barbara J Davis; Mansoor M Amiji; Timothy P Coleman
Journal:  Pharm Res       Date:  2014-03-19       Impact factor: 4.200

6.  99mTc-radiolabeled GE11-modified peptide for ovarian tumor targeting.

Authors:  Najmeh Rahmanian; Seyed Jalal Hosseinimehr; Ali Khalaj; Zohreh Noaparast; Seyed Mohammad Abedi; Omid Sabzevari
Journal:  Daru       Date:  2017-05-02       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.